DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma

Juan Li,Yuan Liang,Jian Fan,Chunru Xu,Bao Guan,Jianye Zhang,Bin Guo,Yue Shi,Ping Wang,Yezhen Tan,Qi Zhang,Changwei Yuan,Yucai Wu,Liqun Zhou,Weimin Ci,Xuesong Li

DOI: https://doi.org/10.1186/s12916-022-02426-w

IF: 9.3

2022-07-20

BMC Medicine

Abstract:At present, the extent and clinical relevance of epigenetic differences between upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB) remain largely unknown. Here, we conducted a study to describe the global DNA methylation landscape of UTUC and UCB and to address the prognostic value of DNA methylation subtype and responses to the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma (UC).

medicine, general & internal